Inhibrx Biosciences is trading at $81.43, down 6.14%, amid the November 5, 2026, market sell-off, with biotech weakness adding pressure. - The supplied context reports steep declines in major indexes and a 5.19% drop in biotech ETF XBI. - No clear company-specific announcement explaining the decline surfaced. The company’s investor page lists a scientific presentation for November 6, rather than a new catalyst identified for November 5.